The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VSTM | +151.33% | -34.38% | -8.07% | -93% |
| S&P | +19.89% | +109.18% | +15.89% | +420% |
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today.
The biotech's experimental cancer treatment won an important regulatory designation today.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.14M | -78.6% |
| Gross Profit | $1.56M | -84.4% |
| Gross Margin | 73.14% | -26.8% |
| Market Cap | $228.04M | 202.2% |
| Market Cap / Employee | $2.92M | 0.0% |
| Employees | 78 | 6.8% |
| Net Income | -$25.93M | -214.1% |
| EBITDA | -$43.64M | -138.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $164.32M | 97.1% |
| Accounts Receivable | $2.08M | -79.2% |
| Inventory | 1.2 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $80.54M | 127.6% |
| Short Term Debt | $4.18M | -35.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -110.30% | -50.1% |
| Return On Invested Capital | -271.74% | -185.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$32.66M | -18.4% |
| Operating Free Cash Flow | -$32.66M | -18.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.26 | 18.82 | -9.35 | -6.59 | -318.95% |
| Price to Sales | 12.04 | 25.18 | 32.67 | 143.78 | 1696.20% |
| Price to Tangible Book Value | 4.26 | 18.82 | -9.35 | -6.59 | -318.94% |
| Enterprise Value to EBITDA | -1.88 | -6.50 | -6.47 | -5.22 | 59.67% |
| Return on Equity | -136.9% | -526.3% | -2159.5% | -437.9% | 298.23% |
| Total Debt | $41.43M | $42.25M | $76.80M | $84.72M | 102.36% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
